Compare PCRX & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | AVXL |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 397.6M |
| IPO Year | 2011 | N/A |
| Metric | PCRX | AVXL |
|---|---|---|
| Price | $20.82 | $4.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $35.33 | $22.00 |
| AVG Volume (30 Days) | 995.1K | ★ 2.1M |
| Earning Date | 02-26-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $716,791,000.00 | N/A |
| Revenue This Year | $6.21 | N/A |
| Revenue Next Year | $8.26 | N/A |
| P/E Ratio | $43.81 | ★ N/A |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $19.84 | $2.86 |
| 52 Week High | $27.64 | $13.99 |
| Indicator | PCRX | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 29.89 | 66.01 |
| Support Level | $22.52 | $4.11 |
| Resistance Level | $26.48 | $4.44 |
| Average True Range (ATR) | 1.21 | 0.27 |
| MACD | -0.61 | 0.18 |
| Stochastic Oscillator | 2.69 | 96.25 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.